General literature
Target 2035: probing the human proteome

Carter AJ., Kraemer O., Zwick M., Mueller-Fahrnow A., Arrowsmith CH., Edwards AM.

Drug Discovery Today 2019, pii: S1359-6446(19)30138-2. open access

DOI
PUBMED
General literature
A probe for every protein: Target 2035 — an ambitious open-science proposal to develop a suite of chemical genomics tools to modulate every protein in the proteome — faces many challenges ahead

Mullard A.

Nature Reviews Drug Discovery 2019. open access

DOI
Success examples
Impedance-based analysis of Natural Killer cell stimulation

Fasbender F., Watzl C.

Scientific Reportsvolume 8, Article number: 4938 (2018)

LFA-1 antagonist
DOI
PubMed
Success examples
Identification of novel azaindazole CCR1 antagonist clinical candidates

Harcken C., Kuzmich D., Cook B., Mao C., Disalvo D., Razavi H., Swinamer A., Liu P., Zhang Q., Kukulka A., Skow D., Patel M., Patel M., Fletcher K., Sherry T., Joseph D., Smith D., Canfield M., Souza D., Bogdanffy M., Berg K., Brown M.

Bioorganic & Medicinal Chemistry Letters 2019, 29, 441-448.

CCR1 antagonist
DOI
PubMed
General literature
Dectin-1 Is a Marker of Alternatively Activated Macrophages and a Therapeutic Target in Interstitial Fibrotic Lung Diseases

Taweel M. E., Walker H., Mekhael O., Vierhout M., Padwal M., Naiel S., Patel H., Parthasarathy P., Imani J., Ayaub E., Naqvi A., Hirota J. A., Hambly N., Kolb M.R.J., Ask K.

ATS Journals 2019. open access

DOI
General literature
An open science rare diseases research initiative: the University of North Carolina Catalyst

Naegeli K., Havener T., Aw W.Y., Anderson E., Morris D.

Future Drug Discovery 2019. open access

DOI